Private Capital Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Private Capital Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Hold	72	–	–	﹤0.01%	1813
2022 Q1	$1K	Sell	72 -22	-23%	-$334	﹤0.01%	2031
2021 Q4	$2K	Hold	94	–	–	﹤0.01%	1864
2021 Q3	$3K	Hold	94	–	–	﹤0.01%	1783
2021 Q2	$3K	Hold	94	–	–	﹤0.01%	1774
2021 Q1	$3K	Hold	94	–	–	﹤0.01%	1707
2020 Q4	$3K	Hold	94	–	–	﹤0.01%	1725
2020 Q3	$2K	Hold	94	–	–	﹤0.01%	1772
2020 Q2	$2K	Hold	94	–	–	﹤0.01%	1751
2020 Q1	$1K	Hold	94	–	–	﹤0.01%	1893
2019 Q4	$1K	Hold	94	–	–	﹤0.01%	1884
2019 Q3	$1K	Buy	+94	New	+$1.15K	﹤0.01%	2121

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Private Capital Group's RVNC Position: Q2 2022 in Review

Private Capital Group held its Revance Therapeutics, Inc. (RVNC) position steady in Q2 2022 at 72 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

Private Capital Group first reported a position in RVNC in Q3 2019 and has held it in 12 quarters since. The position peaked at $3K in Q3 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

Private Capital Group held 72 shares of Revance Therapeutics, Inc. worth $1K as of Q2 2022.
Private Capital Group left its Revance Therapeutics, Inc. share count unchanged in Q2 2022.
Revance Therapeutics, Inc. made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1813 holding.
Private Capital Group first reported a position in Revance Therapeutics, Inc. in Q3 2019 and has held it in 12 quarters since.
Private Capital Group's Revance Therapeutics, Inc. position peaked at $3K in Q3 2021.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.